Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an update.
NeuroSense Therapeutics Ltd. has announced the completion of its 18-month Phase 2b PARADIGM study, showing PrimeC’s potential in slowing ALS disease progression by 33% and enhancing survival rates. The company received positive feedback from the FDA and is on track to start a Phase 3 study in mid-2025. NeuroSense is also preparing for early commercialization in Canada, aiming for a potential launch in 2026. Financially, NeuroSense has strengthened its position with a $5 million private placement, ensuring compliance with Nasdaq’s equity requirements and supporting ongoing clinical developments.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a late-stage clinical biotechnology company focused on developing novel treatments for severe neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company is actively working on PrimeC, a promising treatment aimed at slowing disease progression and improving survival rates in ALS patients.
YTD Price Performance: 39.74%
Average Trading Volume: 213,213
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $25.21M
See more insights into NRSN stock on TipRanks’ Stock Analysis page.
